News & Updates

In the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with extrapelvic soft-tissue metastases that has progressed on an androgen receptor pathway inhibitor (ARPI), the combination of cabozantinib plus atezolizumab appears to prolong progression-free survival (PFS), according to data from the open-label phase 3 CONTACT-02 trial.

Long-term treatment with odevixibat led to sustained improvements in pruritus scores and reductions in serum bile acid (sBA) levels among patients with Alagille syndrome (ALGS), based on a pooled analysis of the phase III ASSERT and ASSERT-EXT studies presented at ESPGHAN 2025.

During outpatient heart failure (HF) care, patients with lower scores in the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) are at greater risk of hospitalizations and mortality, suggests a study. Moreover, those with scores <25 appear to have the highest risk.

One-month treatment with dual antiplatelet therapy (DAPT) results in similar adverse events and a reduction in total bleeding risk when compared with prolonged DAPT, a study has shown.

For patients with schizophrenia being treated with clozapine who have high BMI, semaglutide delivers weight-loss benefits without affecting psychotic symptoms or altering clozapine concentrations, according to the double-blind, phase II COaST study.

Treatment with sildenafil citrate during labour falls short of reducing the incidence of adverse perinatal outcomes potentially related to intrapartum hypoxia, according to a study.

The investigational influenza–COVID-19 combination vaccine mRNA-1083 has demonstrated noninferiority to recommended standard-care flu and COVID-19 vaccines, with higher immune responses and an acceptable safety profile in adults at least 50 years of age, according to the results of a phase III trial.